Claim Missing Document
Check
Articles

Found 2 Documents
Search

A Refined Saccharomyces Cerevisiae-Induced Pyrexia Model In Rats For Specific Antipyretic Preclinical Screening Putra, Oktavian Arya; Wardhani, Bantari Wisynu Kusuma; Riska, Riska; Ramadhan, Nuzula Rijal Nur; Pamungkas, Fajrin Yudha; Al Baariq, Hisyam Nabil Najmuddin; Wahyuningtias , Dita Sheila Putri; Khairunnisa, Rahma; Ulhaq, Oktania Dhiya; Azis, Nurul Magfirah; Guselsa, Fricelia Aura; Siregar, Tika Hafzara; Khairullah, Aswin Rafif
Biomedical Journal of Indonesia Vol. 11 No. 2 (2025): Vol 11, No 2, 2025
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bji.v11i2.265

Abstract

Introduction. A fever-specific, reliable animal model is necessary to screen the antipyretic activity of pharmacological agents, especially to differentiate their action from broad anti-inflammatory activity. The present investigation was directed towards standardizing the yeast-induced pyrexia model in Sprague Dawley rats for screening the antipyretic activity of paracetamol. Methods. Male Sprague Dawley rats were placed into three groups (5 each): normal control, pyrexia-induced untreated, and paracetamol-treated. Pyrexia was induced by subcutaneous injection of 40% aqueous suspension of Saccharomyces cerevisiae (10 mL/kg b.w.). Paracetamol-treated rats were given a single oral dose of 150 mg/kg following pyrexia induction. Rectal temperature was measured at intervals of 30 minutes for 180 minutes. Results. Saccharomyces cerevisiae injection elicited a satisfactory febrile response in both pyrexia-induced groups. In the paracetamol-treated group, there was a considerable decrease in rectal temperature from 90 minutes, and the difference was statistically significant (p < 0.05) when compared with the untreated group. The model was able to distinguish the antipyretic effect of paracetamol from natural thermoregulatory fall in controls. Conclusion. This S. cerevisiae pyrexia model in mice is a specific and reproducible platform for antipyretic drug evaluation. The ability to dissociate antipyretic mechanisms from accompanying inflammatory processes is what makes it an acceptable model for future pharmacological screens. The addition of fever-specific biomarkers, i.e., hypothalamic metabolites and PGE₂, is suggested to also offer mechanistic insight and translational value.
Computational Insights into the Dual Inhibition of PfATP6 and PfCRT by Bioactive Compounds from Spatholobus littoralis Hassk. Wahyuningtias, Dita Sheilla Putri; Putra, Oktavian Arya; Turnip, Laurens Frestasya A.; Ananda, Putu Desy Sagita; Wibowo, Syahputra; Wisynu Kusuma Wardhani, Bantari
Sriwijaya Journal of Medicine Vol. 8 No. 3 (2025): Vol 8, No 3, 2025
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/sjm.v8i3.362

Abstract

The current study examined the antimalarial activity of bioactive compounds extracted from Spatholobus littoralis Hassk. (bajakah wood) by an in-silico approach targeting the Plasmodium falciparum PfCRT and PfATP6 receptors. A total of forty-six phytochemicals were subjected to screening, resulting in the selection of six compounds based on bioactivity prediction, ADMET profiling, and molecular docking analyses.  Ramachandran plots were used to check the accuracy of the model, which showed that the protein structures were reliable.  Milbemycin A4-oxime exhibited the most significant binding affinity (−9.6 kcal/mol for PfCRT and −9.9 kcal/mol for PfATP6). These findings are comparable to or slightly better than those observed for artemisinin in this in silico model. These findings are preliminary and require further experiment. The molecule exhibited persistent interactions and favorable pharmacokinetic properties, indicating its potential use as a multitarget inhibitor.  Quercetin and 8-O-methylretusin had significant efficacy.  These results underscore the potential of S. littoralis metabolites, especially Milbemycin A4-oxime, as candidates for antimalarial drug development; however, additional in vitro and in vivo validation is necessary to establish efficacy and safety.